Herpevax

Recombinant Herpes Simplex Vaccine

RIC Monomer

Complex Formation

Full Protection in 1-2 Doses

Multiple Antigen Display

No Adjuvant Required

Easy to Modify

Protection Against HSV-1 and HSV-2

HerpeVax is a recombinant HSV vaccine that uses the viral glycoprotein D (gD), a proven protective antigen used in viral entry. The vaccine fuses gD to our RIC platform - an IgG scaffold with an epitope tag that forms immune complexes to enhance antigen presentation and eliminate the need for an adjuvant. This platform drives strong neutralizing antibody responses against both HSV-1 and HSV-2, with preclinical data showing a 100-fold increase in gD-specific IgG after a single dose.

Preclinical Proof of Concept: Meeting a Global Unmet Need

  • HSV infects 4B+ people globally; $38B+ market with no approved vaccine to date.

  • HerpeVax shows strong preclinical performance

  • 100× boost in antibody titers after one dose.

  • Neutralizes HSV-1 and HSV-2.

  • Reduces viral shedding in models.

  • No adjuvant needed—self-adjuvanting platform.